组胺-2受体拮抗剂不能预防接受血小板ADP受体拮抗剂单药治疗的动脉粥样硬化性疾病患者消化性溃疡复发:一项随机对照双盲双模拟试验
该随机对照双盲双模拟试验纳入长期使用噻吩吡啶且有消化性溃疡病史的动脉粥样硬化患者,比较法莫替丁40mg睡前服用与安慰剂6个月对复发性消化性溃疡的预防效果。结果显示法莫替丁组与安慰剂组溃疡累积发生率分别为7.0%和11.4%,差异无统计学显著性;法莫替丁不能降低溃疡或溃疡出血发生率,但胃十二指肠糜烂发生率较低。
要点
- 法莫替丁40mg睡前服用6个月未显著降低噻吩吡啶使用者复发性消化性溃疡累积发生率(7.0% vs 11.4%,P=0.239)。
- 法莫替丁组与安慰剂组溃疡出血累积发生率分别为2.6%和1.8%,差异无统计学显著性(P=1.000)。
- 法莫替丁组胃十二指肠糜烂发生率低于安慰剂组(21.1% vs 36.8%,P=0.013)。
核心结论
- 法莫替丁不能降低有消化性溃疡病史且接受噻吩吡啶治疗的动脉粥样硬化性疾病患者的消化性溃疡或溃疡出血发生率。
研究设计与样本
- 随机对照双盲双模拟试验,2012年1月至2016年纳入长期使用噻吩吡啶且有消化性溃疡病史、初始内镜检查无溃疡的患者,随机接受法莫替丁40mg睡前服用或安慰剂睡前服用6个月,法莫替丁组114例、安慰剂组114例。
主要发现
- 6个月期间复发性消化性溃疡累积发生率法莫替丁组7.0%(n=114)vs 安慰剂组11.4%(n=114),差异4.4%(95%CI -11.7至2.9%),P=0.239。
- 溃疡出血累积发生率法莫替丁组2.6% vs 安慰剂组1.8%,差异0.8%(95%CI -0.6至2.4%),P=1.000。
- 胃十二指肠糜烂发生率法莫替丁组21.1% vs 安慰剂组36.8%,差异15.7%(95%CI -27.3至-4.1%),P=0.013,法莫替丁组低于安慰剂组。
关键数值与推荐
- 复发性消化性溃疡累积发生率法莫替丁组7.0% vs 安慰剂组11.4%,差异无统计学显著性(P=0.239)。
- 溃疡出血累积发生率法莫替丁组2.6% vs 安慰剂组1.8%,差异无统计学显著性(P=1.000)。
- 胃十二指肠糜烂发生率法莫替丁组21.1% vs 安慰剂组36.8%,法莫替丁组低于安慰剂组(P=0.013)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Proton pump inhibitor can effectively prevent recurrent peptic ulcers among atherosclerotic patients receiving clopidogrel monotherapy. However, the interaction between proton pump inhibitors and clopidogrel has raised concerns over the safety of combined use of the two medicines in clinical practice. The aims of this randomized-controlled, double-blind and double-dummy trial were to investigate the efficacy of histamine-2 receptor antagonist (H2RA) in the prevention of recurrent peptic ulcer in patients undergoing thienopyridine monotherapy. METHODS: From January 2012 to 2016, long-termed thienopyridine users with a peptic ulcer history who did not have peptic ulcers at initial endoscopy were randomly assigned to receive either famotidine (40 mg, before bedtime) or placebo (before bedtime) for 6 months. Follow-up endoscopy was performed at the end of the 6th month and whenever dyspepsia, hematemesis, or melena occurred. RESULTS: The cumulative incidence of recurrent peptic ulcer during the 6-month period was 7.0% in famotidine group (n=114) and 11.4% in the placebo group (n=114). The two patient groups had comparable cumulative incidence of peptic ulcer (difference, 4.4%; 95% confidence interval (CI), -11.7 to 2.9%; P=0.239). Additionally, there was no difference in the cumulative incidence of ulcer bleeding (2.6% vs. 1.8%; difference, 0.8%; 95% CI, -0.6 to 2.4%, P=1.000) between famotidine and placebo groups. However, the former had a lower incidence of gastroduodenal erosion than the latter (21.1% vs. 36.8%; difference, 15.7%; 95% CI, -27.3 to -4.1%; P=0.013). CONCLUSIONS: Famotidine cannot decrease the incidence of peptic ulcer or ulcer bleeding in thienopyridine users with atherosclerotic disease and a history of peptic ulcer.
引用
- Hsu PI, Wu DC, Tsay FW, et al. Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial. Am J Gastroenterol. 2016. PMID: 27922030. doi:10.1038/ajg.2016.526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。